EspeRare CEO: Proceeds From Dermelix Co-Development Pact To Fund Genetic Pre-Natal Pipeline R&D

 
• By Sten Stovall

The CEO of Swiss not-for-profit foundation EspeRare tells Scrip how she will use funds generated from a co-development pact with Dermelix Biotherapeutics to create novel in utero treatments for rare genetic diseases.

Small shoes for the unborn baby in the belly of pregnant woman
DMX-101 has the potential to correct a genetic disease before birth • Source: Shutterstock

More from Deals

More from Business